ArticleJournal of hepatocellular carcinoma2025
Low Aggregate Index of Systemic Inflammation Values Correlate with Favorable Prognosis and High Abundance of
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Systemic inflammatory response is reported to occupy a crucial role in the progression of hepatocellular carcinoma (HCC). The prognostic significance of SII and PNI in HCC has been explored, but the prognostic significance of aggregate index of systemic inflammation (AISI) in HCC is still unknown. This study was designed to determine the prognostic significance of AISI in HCC and explain the potential underlying mechanisms via gut microbiota and fecal metabolomic profiling. Patients and Methods: A cohort of 109 cases of HCC individuals during January 2023 to August 2024 was included into this clinical research, and the clinical information and fresh fecal samples were collected. The fecal samples were collected for 16S rRNA sequence and metabolomics analysis. Results: Survival analysis revealed that HCC patients in low AISI group tend to experience relatively longer survival time compared with those in high AISI group. Then, we employed ROC analysis to measure the predictive performance of AISI for the survival outcome, and ROC curve showed that levels of AISI had good predictive performance for the survival status with an AUC of 0.771 (95%CI: 0.671-0.871). 16S rRNA sequencing results revealed that levels of Conclusion: AISI is a potential prognostic biomarker in individuals with HCC. A low level of AISI was correlated with high abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.